Given the clear role of MCP-1 in atherosclerosis development and its complications, as well as the association of MCP-1 plasma levels with risk for future and recurrent acute ischemic events, MCP-1 should be further studied as a therapeutic target for the treatment of atherosclerosis. Here, CCL2 is linked to atherosclerosis.